Kyoto University Innovation Capital

Holo Bio is a research and technology firm that specializes in biological breeding techniques to tackle global food challenges. The company has developed a novel organism breeding technology centered around the intestinal bacterium GI35, which was identified in the fish species endemic to Lake Biwa, Isaza. This innovative approach allows Holo Bio to enhance the productivity of polyunsaturated fatty acids (PUFAs) and supply eicosapentaenoic acid (EPA) derived from fish. By transforming previously inedible plant fibers into consumable products, Holo Bio aims to contribute to sustainable food solutions and improve the availability of nutritious resources for society.

KOALA Tech is a high-tech company based in Fukuoka, Japan, focused on developing organic semiconductor laser diodes. Founded in 2019, it aims to enable practical applications of the world's first organic semiconductor laser diode realized at the Center for Organic Photonics and Electronics Research (OPERA) at Kyushu University. The company's laser diode technology is based on organic fluorescent semiconductors, which are generally easier to process into thin films, offering a potentially low-cost light source that can be integrated with organic light-emitting diode and other organic electronic platforms.

Rege Nephro is a Kyoto-based biotechnology company focused on renal disease therapeutics. It conducts research and development, production, and marketing of therapies based on nephron progenitor cells, and develops kidney organoids used to screen nephrotoxicity in drug discovery. The company is leveraging induced pluripotent stem cell technology from the Center for iPS Cell Research and Application at Kyoto University to develop cell-based therapies for kidney conditions, along with potential applications for liver and pancreas diseases. Founded in 2019, Rege Nephro aims to reduce dialysis dependence by addressing renal failure through regenerative approaches.

Grand Green, established in 2017 and headquartered in Nagoya, Japan, specializes in the production of new seeds and seedlings through automatic grafting techniques. As a research and development agribio venture, the company focuses on innovative approaches to enhance agricultural practices and improve crop yield. By leveraging advanced technology in seedling production, Grand Green aims to contribute to the agricultural sector's growth and sustainability.

Toregem BioPharma is a Kyoto, Japan-based startup spun out from Kyoto University that develops dental regenerative medicines. The company focuses on therapeutic agents for congenital adentia and aims to restore dentition by regenerating teeth from a patient’s own tissues, with research and development aimed at treating tooth loss due to decay or periodontal disease and improving oral health.

Rege Nephro is a Kyoto-based biotechnology company focused on renal disease therapeutics. It conducts research and development, production, and marketing of therapies based on nephron progenitor cells, and develops kidney organoids used to screen nephrotoxicity in drug discovery. The company is leveraging induced pluripotent stem cell technology from the Center for iPS Cell Research and Application at Kyoto University to develop cell-based therapies for kidney conditions, along with potential applications for liver and pancreas diseases. Founded in 2019, Rege Nephro aims to reduce dialysis dependence by addressing renal failure through regenerative approaches.

Myoridge Co. Ltd., established in 2016 and headquartered in Kyoto, Japan, specializes in developing a suspension culture system for scalable differentiation of pluripotent cells into desired cell types, notably cardiomyocytes. The company's innovative process employs a proprietary small-molecule compound, eliminating the need for proteins, thereby reducing production costs and ensuring lot-to-lot uniformity. Myoridge offers iPS cell-derived cardiomyocytes, cardiomyocyte fibers, and software for myocardial motion/fluorescence analysis, enabling advancements in regenerative medicine and drug discovery research.

Perseus Proteomics Inc. is a biotechnology company based in Tokyo, Japan, focused on drug discovery. Established in 2001, it specializes in antibody discovery, engineering, and research support activities. The company engages in target discovery and functional protein expression, offering services such as mouse hybridoma sequencing, recombinant protein production, and contract research for antibodies. Additionally, Perseus Proteomics develops, manufactures, and supplies a range of antibody products. By leveraging advanced antibody technology, the company aims to create innovative medicines that address the needs of patients worldwide seeking improved medical care.

Founded in Kyoto, Japan in 2019, Kyoto Fusioneering is a privately funded technology company focused on developing advanced technologies for commercial fusion reactors. Their work includes gyrotron systems, tritium fuel cycle technologies, and breeding blankets for tritium production and power generation. The company aims to accelerate the realization of fusion energy as a viable, carbon-free power source.

Toregem BioPharma is a Kyoto, Japan-based startup spun out from Kyoto University that develops dental regenerative medicines. The company focuses on therapeutic agents for congenital adentia and aims to restore dentition by regenerating teeth from a patient’s own tissues, with research and development aimed at treating tooth loss due to decay or periodontal disease and improving oral health.

FLOSFIA INC. is a Tokyo-based company that focuses on the development of corundum structured Gallium Oxide semiconductor power devices. Founded on March 31, 2011, the company emerged as a spin-off from research conducted at Kyoto University. FLOSFIA specializes in film-formation using mist chemical vapor deposition (CVD) techniques, leveraging the unique physical properties of gallium oxide (Ga2O3) to create high breakdown voltage and high efficiency power devices. The firm is dedicated to advancing low-loss power device technology, contributing to the evolution of semiconductor applications.

Rege Nephro is a Kyoto-based biotechnology company focused on renal disease therapeutics. It conducts research and development, production, and marketing of therapies based on nephron progenitor cells, and develops kidney organoids used to screen nephrotoxicity in drug discovery. The company is leveraging induced pluripotent stem cell technology from the Center for iPS Cell Research and Application at Kyoto University to develop cell-based therapies for kidney conditions, along with potential applications for liver and pancreas diseases. Founded in 2019, Rege Nephro aims to reduce dialysis dependence by addressing renal failure through regenerative approaches.

Founded in Tokyo, Japan in 2012, Tiem Factory specializes in the research, development, manufacturing, and sale of aerogel under the brand SUFA. The company's primary product is an ultra-light transparent insulation material designed for thermal insulation applications.

LegalForce, Inc. is a Tokyo-based company founded in 2017 that specializes in developing software for legal services. It operates an AI-powered contract management platform designed to assist legal professionals in contract review. By utilizing natural language processing and other advanced technologies, LegalForce's platform helps users analyze contracts based on their specific types, while identifying potentially omitted or risky clauses. This functionality aids legal professionals in preventing oversights and enhancing the quality and efficiency of their operations, ultimately strengthening their legal systems.

LegalOn is an AI-driven platform specializing in contract review. It leverages AI, legal content, and team knowledge to identify potential risks, suggest redlines, and structure contract data, thereby enhancing efficiency in legal processes.

Founded in Kyoto, Japan in 2019, Kyoto Fusioneering is a privately funded technology company focused on developing advanced technologies for commercial fusion reactors. Their work includes gyrotron systems, tritium fuel cycle technologies, and breeding blankets for tritium production and power generation. The company aims to accelerate the realization of fusion energy as a viable, carbon-free power source.

Myoridge Co. Ltd., established in 2016 and headquartered in Kyoto, Japan, specializes in developing a suspension culture system for scalable differentiation of pluripotent cells into desired cell types, notably cardiomyocytes. The company's innovative process employs a proprietary small-molecule compound, eliminating the need for proteins, thereby reducing production costs and ensuring lot-to-lot uniformity. Myoridge offers iPS cell-derived cardiomyocytes, cardiomyocyte fibers, and software for myocardial motion/fluorescence analysis, enabling advancements in regenerative medicine and drug discovery research.

Space Power Technologies is a Japanese company founded in 2019, specializing in the development and manufacturing of microwave-based wireless power transmission systems. As Japan's first start-up focused on spatial transmission wireless power transmission, the company aims to address societal power supply challenges by integrating advanced technologies with practical applications. Its innovative systems offer diverse usage scenarios, including factories, logistics sites, infrastructure monitoring, depopulated areas lacking power wiring, disaster recovery situations, and even outer space. By enabling wireless power transfer over distances using radio waves, Space Power Technologies seeks to contribute to the creation of a wireless society, enhancing efficiency and accessibility in power delivery.

AlphaNavi Pharma Co., Ltd. is a biotechnology company based in Kyoto, Japan, founded in 2019. The company focuses on drug discovery, specifically developing novel therapeutics for pain management. It is engaged in research and development of voltage-gated sodium channel selective inhibitors, with its primary products being ANP-230 and ANP-231, which are aimed at treating peripheral neuropathic pain. AlphaNavi Pharma collaborates with academic institutions and investors to enhance its research and clinical development efforts, striving to create innovative analgesic drugs that alleviate pain for patients and improve their quality of life.

Chordia Therapeutics Inc. is a clinical-stage biotechnology company based in Fujisawa, Japan, founded in 2017. The company specializes in the research and development of innovative oncology drugs, focusing on delivering first-in-class therapies for cancers that currently have high unmet medical needs. Chordia Therapeutics is committed to advancing new therapeutic options to patients as swiftly as possible, aiming to address significant gaps in cancer treatment.

SOUSEI Technology, Inc., established in 2018 and headquartered in Tokyo, specializes in developing innovative home design and management solutions. The company offers an IoT device called v-ex, enabling voice-activated communication with home electronics. Additionally, SOUSEI provides Knot, an online platform facilitating connections between housing companies and homeowners while streamlining customer and property information management, documents, and security compliance.

LegalOn is an AI-driven platform specializing in contract review. It leverages AI, legal content, and team knowledge to identify potential risks, suggest redlines, and structure contract data, thereby enhancing efficiency in legal processes.

LegalForce, Inc. is a Tokyo-based company founded in 2017 that specializes in developing software for legal services. It operates an AI-powered contract management platform designed to assist legal professionals in contract review. By utilizing natural language processing and other advanced technologies, LegalForce's platform helps users analyze contracts based on their specific types, while identifying potentially omitted or risky clauses. This functionality aids legal professionals in preventing oversights and enhancing the quality and efficiency of their operations, ultimately strengthening their legal systems.

LegalForce, Inc. is a Tokyo-based company founded in 2017 that specializes in developing software for legal services. It operates an AI-powered contract management platform designed to assist legal professionals in contract review. By utilizing natural language processing and other advanced technologies, LegalForce's platform helps users analyze contracts based on their specific types, while identifying potentially omitted or risky clauses. This functionality aids legal professionals in preventing oversights and enhancing the quality and efficiency of their operations, ultimately strengthening their legal systems.

LegalOn is an AI-driven platform specializing in contract review. It leverages AI, legal content, and team knowledge to identify potential risks, suggest redlines, and structure contract data, thereby enhancing efficiency in legal processes.

Questetra, Inc. is an enterprise cloud computing company based in Kyoto, Japan, founded in 2008. It specializes in providing business process management (BPM) tools designed to enhance productivity and optimize various workflows for organizations. The Questetra BPM Suite allows users to independently develop and manage BPMN-driven workflows through a 100% web-based interface, enabling both process design and task execution directly in a browser. The platform includes a variety of sample processes, such as estimate generation and invoice issuance, and offers seamless integration with Google Apps, allowing users to log in with their Google accounts and export data to Google Docs. Additionally, Questetra provides BPM consulting services to further support organizations in their process improvement initiatives.

Chordia Therapeutics Inc. is a clinical-stage biotechnology company based in Fujisawa, Japan, founded in 2017. The company specializes in the research and development of innovative oncology drugs, focusing on delivering first-in-class therapies for cancers that currently have high unmet medical needs. Chordia Therapeutics is committed to advancing new therapeutic options to patients as swiftly as possible, aiming to address significant gaps in cancer treatment.

Stem Cell & Device Laboratory, Inc. is a research and development company based in Kyoto, Japan, focused on the manufacturing and sale of cells, devices, and integrated products that utilize cell materials for drug discovery applications. Founded in 2014, the company specializes in developing innovative scaffold materials that demonstrate functional and cell compatibility, particularly for studies involving pluripotent stem cells. By leveraging advanced micro-engineering and nanofabrication technologies, Stem Cell & Device Laboratory aims to contribute to advancements in cell application products that support the health and well-being of society.

FLOSFIA INC. is a Tokyo-based company that focuses on the development of corundum structured Gallium Oxide semiconductor power devices. Founded on March 31, 2011, the company emerged as a spin-off from research conducted at Kyoto University. FLOSFIA specializes in film-formation using mist chemical vapor deposition (CVD) techniques, leveraging the unique physical properties of gallium oxide (Ga2O3) to create high breakdown voltage and high efficiency power devices. The firm is dedicated to advancing low-loss power device technology, contributing to the evolution of semiconductor applications.

Founded in Tokyo, Japan in 2012, Tiem Factory specializes in the research, development, manufacturing, and sale of aerogel under the brand SUFA. The company's primary product is an ultra-light transparent insulation material designed for thermal insulation applications.

Stem Cell & Device Laboratory, Inc. is a research and development company based in Kyoto, Japan, focused on the manufacturing and sale of cells, devices, and integrated products that utilize cell materials for drug discovery applications. Founded in 2014, the company specializes in developing innovative scaffold materials that demonstrate functional and cell compatibility, particularly for studies involving pluripotent stem cells. By leveraging advanced micro-engineering and nanofabrication technologies, Stem Cell & Device Laboratory aims to contribute to advancements in cell application products that support the health and well-being of society.